Pharmaceutical Investing RedHill Biopharma Announces Completion of Enrollment for Confirmatory Phase III Study with TALICIA for H. pylori Infection
RedHill Biopharma Receives Allowance for New U.S. Patent Covering RHB-106, an Encapsulated Bowel Preparation
Pharmaceutical Investing RedHill Biopharma Initiates Co-Promotion of HIV/AIDS Anti-Diarrheal Drug Mytesi®
Juggernaut Announces Strategic Investment by Crescat Capital Funds for 28.95% Ownership - Dr. Quinton Hennigh Technical Advisor
